Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allon Therapeutics has received $625,000 in Michael J Fox Foundation (MJFF) grant to conduct pre-clinical research that will help determine the potential of the company's lead neuroprotective drug, Davunetide, as a treatment for parkinson's disease (PD).
Subscribe to our email newsletter
The newly funded research project will focus on the impact of Davunetide on a key pathology in PD, namely alpha-synuclein.
Allon said that a previous preclinical project, also sponsored by MJFF, showed that Davunetide had a positive effect in both in-vitro and in-vivo models of PD.
The company has already completed Phase 2 clinical trials in which the efficacy of Davunetide has been demonstrated in patients with amnestic mild cognitive impairment, a precursor to alzheimer’s disease, and cognitive impairment associated with schizophrenia.
MJFF chief program officer Todd Sherer said that because Davunetide is already in clinical trials for progressive supranuclear palsy, a rare progressive movement disorder, the potential exists to rapidly bridge to a clinical trial in PD.